DelfaGLP-1 Atlas

← Trials/Trial dossier/NCT06836037

CompletedPhase 1

A Clinical Study of Efinopegdutide (MK-6024) in Healthy Chinese Volunteers (MK-6024-011)

A Single and Multiple Dose Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics of MK-6024 in Healthy Chinese Participants

Asset

Efinopegdutide

Subcutaneous · GLP-1 / glucagon dual

Listed sites

1

Recruiting sites

—

Enrollment

56

actual

Study population

Healthy volunteers, Obesity / overweight

Key I/E criterion

•BMI 25-35

Primary endpoints

•Treatment-emergent AEs (any)•Discontinuation due to AE•Cmax of Efinopegdutide- single dose

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT06836037
Org study ID6024-011
Secondary ID2020-005136-30EU CT
Secondary IDMK-6024-011MSD

Timeline

Milestones

Study start2022-09-05actual
Primary completion2023-02-02actual
Study completion2023-02-02actual
Study first posted2025-02-20actual
Last update posted2025-02-21actual

Assets

Investigational agents

Efinopegdutide

Study populations

Who this study enrolls

Healthy volunteersObesity / overweight

Eligibility

Who can enroll

Minimum age20 Years
Maximum age60 Years
SexAll
Healthy volunteersAccepted

Inclusion criteria

The key inclusion criteria include but are not limited to the following:

•Is in good health before randomization
•Has a body mass index (BMI) ≥25 and ≤35 kg/m^2

Exclusion criteria

The key exclusion criteria include but are not limited to the following:

•Has a history of clinically significant endocrine, gastrointestinal (GI), cardiovascular, hematological, hepatic, immunological, renal, respiratory, genitourinary, or major neurological (including stroke and chronic seizures) abnormalities or diseases
•Had major surgery, donated or lost approximately 400 mL blood within 4 weeks prior to entering the study

Endpoints (23)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Safety / tolerability / PK
18
Cardiometabolic biomarkers
4
Weight & body composition
1

Weight & body composition

1 endpoint
Secondary/protocol endpoint

Change from Baseline in Weight

Time frame:Baseline and day 112

Body weight, absolute change (kg)

change from baseline, improvement

Cardiometabolic biomarkers

4 endpoints
Secondary/protocol endpoint

Change from Baseline in HDL Cholesterol

Time frame:Baseline and day 112

HDL-C, change

change from baseline, improvement

LOINC 2085-9

Secondary/protocol endpoint

Change from Baseline in LDL Cholesterol

Time frame:Baseline and day 112

LDL-C, change

change from baseline, improvement

LOINC 13457-7

Secondary/protocol endpoint

Change from Baseline in Total Cholesterol

Time frame:Baseline and day 112

Total cholesterol, change

change from baseline, improvement

LOINC 2093-3

Secondary/protocol endpoint

Change from Baseline in Triglycerides

Time frame:Baseline and day 112

Triglycerides, change

change from baseline, improvement

LOINC 2571-8

Safety / tolerability / PK

18 endpoints
Primary/protocol endpoint

Number of Participants Who Experience an Adverse Event (AE)

Time frame:Up to approximately 112 days

Treatment-emergent AEs (any)

event count, event

Primary/protocol endpoint

Number of Participants Who Discontinue Study Treatment Due to an AE

Time frame:Up to approximately 78 days

Discontinuation due to AE

event count, event

Primary/protocol endpoint

Maximum Plasma Concentration (Cmax) of Efinopegdutide- single dose

Time frame:At designated time points up to 35 days

Cmax

concentration, descriptive

Primary/protocol endpoint

Time to Maximum Plasma Concentration (Tmax) of Efinopegdutide- single dose

Time frame:At designated time points up to 35 days

Tmax

descriptive

Primary/protocol endpoint

Area Under the Concentration-Time Curve from Time 0 to Last (AUC0-Last) of Efinopegdutide- single dose

Time frame:At designated timepoints up to 35 days

concentration, descriptive

Primary/protocol endpoint

Area Under the Concentration-Time Curve from Time 0 to Infinity (AUC0-inf) of Efinopegdutide- single dose

Time frame:At designated timepoints up to 35 days

AUC₀–∞

concentration, descriptive

Primary/protocol endpoint

Terminal half life (t1/2) of Efinopegdutide- single dose

Time frame:At designated timepoints up to 35 days

Half-life

descriptive

Primary/protocol endpoint

Apparent Clearance (CL) of Efinopegdutide- single dose

Time frame:At designated timepoints up to 35 days

descriptive

Primary/protocol endpoint

Volume of Distribution (Vz) of Efinopegdutide- single dose

Time frame:At designated timepoints up to 35 days

descriptive

Primary/protocol endpoint

Maximum Plasma Concentration (Cmax) of Efinopegdutide- multiple dose

Time frame:At designated time points up to 112 days

Cmax

concentration, descriptive

Primary/protocol endpoint

Minimum Plasma Concentration (Cmin) of Efinopegdutide- multiple dose

Time frame:At designated time points up to 112 days

Plasma concentration (steady state)

concentration, descriptive

Primary/protocol endpoint

Time to Maximum Plasma Concentration (Tmax) of Efinopegdutide- multiple dose

Time frame:At designated time points up to 112 days

Tmax

descriptive

Primary/protocol endpoint

Terminal half life (t1/2) of Efinopegdutide- multiple dose

Time frame:At designated timepoints up to 112 days

Half-life

descriptive

Primary/protocol endpoint

Area Under the Concentration-Time Curve from Time 0 to Last (AUC0-Last) of Efinopegdutide-multiple dose

Time frame:At designated timepoints up to 112 days

concentration, descriptive

Primary/protocol endpoint

Apparent Clearance (CL) of Efinopegdutide- multiple dose

Time frame:At designated timepoints up to 112 days

descriptive

Primary/protocol endpoint

Volume of Distribution at Steady State (Vss) of Efinopegdutide- multiple dose

Time frame:At designated timepoints up to 112 days

descriptive

Primary/protocol endpoint

Area Under the Concentration-Time Curve to the end of the dosing period (AUC 0-tau)of Efinopegdutide- multiple dose

Time frame:At designated timepoints up to 78 days

AUC₀–∞

concentration, descriptive

Secondary/protocol endpoint

Number of participants with anti drug antibodies (ADA) to efinopegdutide

Time frame:At designated timepoints up to 112 days

Immunogenicity (ADA)

descriptive

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 1, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.